Search Results for: TRAF6

Novel Symbol Description Pathways Hide Drugs Hide Diseases Hide
SQSTM1 sequestosome 1
  • NRIF signals cell death from the nucleus
  • p75NTR recruits signalling complexes
  • NF-kB is activated and signals survival
  • PINK1-PRKN Mediated Mitophagy
  • Neddylation
  • Interleukin-1 signaling
  • Pexophagy
  • Signaling by ALK fusions and activated point mutants
  • KEAP1-NFE2L2 pathway
  • Nuclear events mediated by NFE2L2
  • Paget's disease of bone and related disorders, including: ; Paget's disease of bone (PDB); Familial expansile osteolysis (FEO); Early-onset Paget's disease of bone (PDB2); Expansile skeletal hyperphosphatasia (ESH); Juvenile Paget's disease (JPD)
SRC SRC proto-oncogene, non-receptor tyrosine kinase
  • Signaling by ERBB2
  • Nuclear signaling by ERBB4
  • Downregulation of ERBB4 signaling
  • PIP3 activates AKT signaling
  • GAB1 signalosome
  • Downstream signal transduction
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Integrin signaling
  • GRB2:SOS provides linkage to MAPK signaling for Integrins
  • p130Cas linkage to MAPK signaling for integrins
  • G alpha (s) signalling events
  • G alpha (i) signalling events
  • G alpha (i) signalling events
  • DCC mediated attractive signaling
  • DCC mediated attractive signaling
  • Netrin mediated repulsion signals
  • Regulation of commissural axon pathfinding by SLIT and ROBO
  • RAF activation
  • MAP2K and MAPK activation
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by high-kinase activity BRAF mutants
  • Signaling by BRAF and RAF1 fusions
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • MET activates PTK2 signaling
  • InlA-mediated entry of Listeria monocytogenes into host cells
  • Regulation of RUNX1 Expression and Activity
  • RUNX2 regulates osteoblast differentiation
  • Regulation of RUNX3 expression and activity
  • Extra-nuclear estrogen signaling
  • RHOU GTPase cycle
  • Activated NTRK2 signals through FYN
  • Activated NTRK3 signals through PI3K
  • Activated NTRK3 signals through PI3K
  • Long-term potentiation
  • GPER1 signaling
  • Signaling downstream of RAS mutants
  • Signaling by RAF1 mutants
  • Signaling by CSF1 (M-CSF) in myeloid cells
  • Degradation of CDH1
  • Dasatinib
  • RU84687
  • RU79256
  • N6-Benzyl Adenosine-5'-Diphosphate
  • RU85493
  • RU78262
  • Phosphonotyrosine
  • Malonic acid
  • RU83876
  • RU90395
  • RU79072
  • RU78783
  • 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine
  • PASBN
  • 2-[4-[(Z)-2-Acetamido-3-oxo-3-[[(3S)-2-oxo-1-[(4-phenylphenyl)methyl]azepan-3-yl]amino]prop-1-enyl]-2-formylphenyl]acetic acid
  • PAS219
  • DPI59
  • RU82197
  • Phenylphosphate
  • RU78300
  • RU79073
  • RU82209
  • ISO24
  • RU85053
  • RU78299
  • Oxalic Acid
  • RU78191
  • Citric acid
  • Paratoulene phosphate
  • 4-[(4-METHYL-1-PIPERAZINYL)METHYL]-N-[3-[[4-(3-PYRIDINYL)-2-PYRIMIDINYL]AMINO]PHENYL]-BENZAMIDE
  • Purvalanol A
  • XL228
  • Tirbanibulin
  • Bosutinib
  • 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea
  • 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-phenylurea
  • 3-[4-AMINO-1-(1-METHYLETHYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL]PHENOL
  • PD-168393
  • [4-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl}amino)phenyl]acetonitrile
  • PP-121
  • 1-cyclobutyl-3-(3,4-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
  • 1-(1-methylethyl)-3-quinolin-6-yl-1H-pyrazolo[3,4-d]pyrimidin-4-amine
  • 2-(4-CARCOXY-5-ISOPROPYLTHIAZOLYL)BENZOPIPERIDINE
  • N-(4-PHENYLAMINO-QUINAZOLIN-6-YL)-ACRYLAMIDE
  • (2E)-N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide
  • Ponatinib
  • Nintedanib
  • Fostamatinib
STAMBP STAM binding protein
  • Metalloprotease DUBs
STK17A serine/threonine kinase 17a
  • Fostamatinib
STK26 serine/threonine kinase 26
  • Apoptotic cleavage of cellular proteins
  • 2-[4-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl]iminocyclohexa-2,5-dien-1-yl]acetonitrile
  • Fostamatinib
STRADB STE20 related adaptor beta
  • Energy dependent regulation of mTOR by LKB1-AMPK
STUB1 STIP1 homology and U-box containing protein 1
  • Downregulation of TGF-beta receptor signaling
  • RIPK1-mediated regulated necrosis
  • Regulation of TNFR1 signaling
  • Regulation of necroptotic cell death
  • Downregulation of ERBB2 signaling
  • Regulation of RUNX2 expression and activity
  • Regulation of PTEN stability and activity
  • Antigen processing: Ubiquitination & Proteasome degradation
SUFU SUFU negative regulator of hedgehog signaling
  • Degradation of GLI1 by the proteasome
  • Degradation of GLI1 by the proteasome
  • Degradation of GLI2 by the proteasome
  • GLI3 is processed to GLI3R by the proteasome
  • Hedgehog 'off' state
  • Hedgehog 'on' state
  • Basal cell nevus syndrome; Nevoid basal cell carcinoma syndrome; Gorlin syndrome
SYK spleen associated tyrosine kinase
  • GPVI-mediated activation cascade
  • GPVI-mediated activation cascade
  • FCGR activation
  • FCGR activation
  • Regulation of actin dynamics for phagocytic cup formation
  • Role of phospholipids in phagocytosis
  • DAP12 signaling
  • Fc epsilon receptor (FCERI) signaling
  • Fc epsilon receptor (FCERI) signaling
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • FCERI mediated MAPK activation
  • FCERI mediated Ca+2 mobilization
  • FCERI mediated Ca+2 mobilization
  • Integrin signaling
  • CLEC7A (Dectin-1) signaling
  • Dectin-2 family
  • Dectin-2 family
  • Interleukin-2 signaling
  • Regulation of signaling by CBL
  • Regulation of signaling by CBL
  • FCGR3A-mediated IL10 synthesis
  • FCGR3A-mediated phagocytosis
  • Signaling by CSF3 (G-CSF)
  • Signaling by CSF3 (G-CSF)
  • Potential therapeutics for SARS
  • Inactivation of CSF3 (G-CSF) signaling
  • Inactivation of CSF3 (G-CSF) signaling
  • FLT3 signaling through SRC family kinases
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Staurosporine
  • N-(2-hydroxy-1,1-dimethylethyl)-1-methyl-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)-1H-indole-5-carboxamide
  • Tamatinib
  • 2-{2-[(3,5-dimethylphenyl)amino]pyrimidin-4-yl}-N-[(1S)-2-hydroxy-1-methylethyl]-4-methyl-1,3-thiazole-5-carboxamide
  • 2-{[(1R,2S)-2-aminocyclohexyl]amino}-4-[(3-methylphenyl)amino]pyrimidine-5-carboxamide
  • Ellagic acid
  • Fostamatinib
  • Entospletinib
TAB1 TGF-beta activated kinase 1 (MAP3K7) binding protein 1
  • NOD1/2 Signaling Pathway
  • FCERI mediated NF-kB activation
  • TAK1-dependent IKK and NF-kappa-B activation
  • activated TAK1 mediates p38 MAPK activation
  • JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1
  • TNFR1-induced NF-kappa-B signaling pathway
  • CLEC7A (Dectin-1) signaling
  • Ub-specific processing proteases
  • TICAM1,TRAF6-dependent induction of TAK1 complex
  • Interleukin-1 signaling
  • IRAK2 mediated activation of TAK1 complex
  • TRAF6-mediated induction of TAK1 complex within TLR4 complex
  • Alpha-protein kinase 1 signaling pathway
  • SARS-CoV-2 activates/modulates innate and adaptive immune responses
  • IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation
  • Manganese
TAB2 TGF-beta activated kinase 1 (MAP3K7) binding protein 2
  • Nuclear signaling by ERBB4
  • Nuclear signaling by ERBB4
  • NOD1/2 Signaling Pathway
  • Downstream TCR signaling
  • FCERI mediated NF-kB activation
  • TAK1-dependent IKK and NF-kappa-B activation
  • activated TAK1 mediates p38 MAPK activation
  • JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1
  • TNFR1-induced NF-kappa-B signaling pathway
  • CLEC7A (Dectin-1) signaling
  • TICAM1,TRAF6-dependent induction of TAK1 complex
  • Interleukin-1 signaling
  • IRAK2 mediated activation of TAK1 complex
  • TRAF6-mediated induction of TAK1 complex within TLR4 complex
  • Alpha-protein kinase 1 signaling pathway
  • SARS-CoV-2 activates/modulates innate and adaptive immune responses
  • IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation
TAB3 TGF-beta activated kinase 1 (MAP3K7) binding protein 3
  • NOD1/2 Signaling Pathway
  • FCERI mediated NF-kB activation
  • TAK1-dependent IKK and NF-kappa-B activation
  • activated TAK1 mediates p38 MAPK activation
  • JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1
  • TNFR1-induced NF-kappa-B signaling pathway
  • CLEC7A (Dectin-1) signaling
  • TICAM1,TRAF6-dependent induction of TAK1 complex
  • Interleukin-1 signaling
  • IRAK2 mediated activation of TAK1 complex
  • TRAF6-mediated induction of TAK1 complex within TLR4 complex
  • Alpha-protein kinase 1 signaling pathway
  • SARS-CoV-2 activates/modulates innate and adaptive immune responses
  • IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation
TANK TRAF family member associated NFKB activator
  • TICAM1-dependent activation of IRF3/IRF7
  • TRAF6 mediated IRF7 activation
  • Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE)
  • Regulation of TBK1, IKKε (IKBKE)-mediated activation of IRF3, IRF7
  • Regulation of TBK1, IKKε-mediated activation of IRF3, IRF7 upon TLR3 ligation
TAX1BP1 Tax1 binding protein 1
  • Regulation of TNFR1 signaling
  • Negative regulators of DDX58/IFIH1 signaling
TDP2 tyrosyl-DNA phosphodiesterase 2
  • Nonhomologous End-Joining (NHEJ)
TGFBR1 transforming growth factor beta receptor 1
  • Downregulation of TGF-beta receptor signaling
  • Downregulation of TGF-beta receptor signaling
  • TGF-beta receptor signaling activates SMADs
  • TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
  • TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
  • SMAD2/3 Phosphorylation Motif Mutants in Cancer
  • TGFBR2 Kinase Domain Mutants in Cancer
  • TGFBR1 KD Mutants in Cancer
  • TGFBR1 LBD Mutants in Cancer
  • UCH proteinases
  • Ub-specific processing proteases
  • TGFBR3 regulates TGF-beta signaling
  • 4-(3-Pyridin-2-Yl-1h-Pyrazol-4-Yl)Quinoline
  • Naphthyridine Inhibitor
  • 3-(4-Fluorophenyl)-2-(6-Methylpyridin-2-Yl)-5,6-Dihydro-4h-Pyrrolo[1,2-B]Pyrazole
  • N-[4-(5-fluoro-6-methylpyridin-2-yl)-5-quinoxalin-6-yl-1H-imidazol-2-yl]acetamide
  • 2-(6-methylpyridin-2-yl)-N-pyridin-4-ylquinazolin-4-amine
  • N-1H-indazol-5-yl-2-(6-methylpyridin-2-yl)quinazolin-4-amine
  • Fostamatinib
  • Loeys-Dietz syndrome (LDS)
  • Familial thoracic aortic aneurysm and dissection (TAAD); Aortic aneurysm familial thoracic type (AAT)
TICAM1 TIR domain containing adaptor molecule 1
  • Caspase activation via Death Receptors in the presence of ligand
  • MyD88-independent TLR4 cascade
  • Toll Like Receptor 3 (TLR3) Cascade
  • TICAM1, RIP1-mediated IKK complex recruitment
  • RIP-mediated NFkB activation via ZBP1
  • TRIF-mediated programmed cell death
  • TICAM1 deficiency - HSE
  • TRAF3 deficiency - HSE
  • TLR3-mediated TICAM1-dependent programmed cell death
  • TICAM1-dependent activation of IRF3/IRF7
  • TICAM1,TRAF6-dependent induction of TAK1 complex
  • Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE)
  • IKK complex recruitment mediated by RIP1
  • TRAF6-mediated induction of TAK1 complex within TLR4 complex
  • IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation
  • Regulation of TBK1, IKKε (IKBKE)-mediated activation of IRF3, IRF7
  • Regulation of TBK1, IKKε-mediated activation of IRF3, IRF7 upon TLR3 ligation
TICAM2 TIR domain containing adaptor molecule 2
  • Caspase activation via Death Receptors in the presence of ligand
  • Toll Like Receptor 4 (TLR4) Cascade
  • MyD88-independent TLR4 cascade
  • TRIF-mediated programmed cell death
  • Neutrophil degranulation
  • Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE)
  • IKK complex recruitment mediated by RIP1
  • TRAF6-mediated induction of TAK1 complex within TLR4 complex
  • IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation
  • Regulation of TBK1, IKKε (IKBKE)-mediated activation of IRF3, IRF7
TIFA TRAF interacting protein with forkhead associated domain
  • TAK1-dependent IKK and NF-kappa-B activation
  • Alpha-protein kinase 1 signaling pathway
TIRAP TIR domain containing adaptor protein
  • ER-Phagosome pathway
  • MyD88:MAL(TIRAP) cascade initiated on plasma membrane
  • MyD88 deficiency (TLR2/4)
  • IRAK4 deficiency (TLR2/4)

Page 7 out of 10 pages